VANCOUVER, BC, April 27, 2026 (GLOBE NEWSWIRE) — VVT Med Inc. (TSXV: VVTM) (“VVT Med” or the “Company”), a pace-setter in next-generation, minimally invasive, non-thermal, and non-tumescent (“NT-NT”) answers for venous illness, is happy to announce that it has entered into its greatest Ecu distribution settlement thus far, a strategic unique distribution partnership with Uber Ros S.p.A. (“Uber Ros”) for the commercialization of its ScleroSafe® device in Italy, Vatican Town and the Republic of San Marino (the “Territory”).
Underneath the phrases of the settlement, signed on April ninth, 2026, Uber Ros will function the Corporate’s unique distributor within the Territory. The five-year settlement represents roughly CAD $2.3 million in possible income to the Corporate, in keeping with agreed minimal acquire commitments, with a portion structured below a pay-or-buy mechanism that gives an outlined stage of business dedication from the distributor, topic to the phrases of the settlement.
Italy is a vital and strategically essential healthcare marketplace, with a well-established community of vascular and phlebology experts. The partnership with Uber Ros permits VVT Med to get admission to this marketplace via an skilled and dedicated native business spouse, supporting doctor training and product adoption around the Territory.
ScleroSafe® is FDA-cleared and CE-marked, enabling its deployment throughout the Ecu Union’s regulatory framework. The Corporate’s NT-NT era addresses the widest vary of vein diameters, enabling physicians to regard each the clinical and aesthetic facets of venous illness via a proprietary, simultaneous sclerosant injection and blood aspiration procedure, without a anesthesia and no downtime
“We are very excited to begin this journey with VVT Med,” mentioned Giorgio Rosati, Proprietor of Uber Ros S.p.A. “ScleroSafe integrates perfectly with our existing portfolio in the vascular segment and represents a natural extension of our offering to physicians.”
“I am also particularly pleased that this agreement comes in a very special year for our company, as we celebrate our 40th anniversary. Over the years, Uber Ros has grown into one of the leading medical device distributors in Italy, representing highly prestigious international brands across multiple specialties, including vascular, orthopedics, trauma, spine, maxillofacial, ENT, and neurosurgery.”
“This partnership further strengthens our commitment to bringing innovative and effective solutions to the Italian healthcare system.”
“This agreement marks another important step in executing our strategy to build a focused international distribution network with committed partners,” mentioned Erez Tetro, Leader Government Officer of VVT Med. “We believe Italy represents a compelling opportunity for ScleroSafe, and this partnership, our largest European agreement to date, reflects the growing commercial traction of our platform and the confidence that experienced regional partners are placing in our technology.”
Along with the economic partnership, Uber Ros has joined the Corporate’s prior to now introduced non-brokered non-public placement financing (the “Offering”) as an investor, additional aligning business execution with strategic funding, topic to normal stipulations and, the place required, ultimate acceptance through the TSX Undertaking Trade. This participation displays the conviction of the Corporate’s distribution companions within the long-term price of VVT Med’s era platform.
The Providing stays topic to normal stipulations and, the place required, ultimate acceptance through the TSX Undertaking Trade. There may also be no assurance that the whole minimal acquire commitments will probably be learned or that the non-public placement will probably be finished at the phrases described or in any respect.
The settlement has an preliminary non-cancellable time period of 3 (3) months (the “Initial Term”), right through which the Corporate is needed to pay an mixture charge of US$37,500 (US$12,500 per thirty days), adopted through automated quarterly renewals at a charge of US$12,500 per thirty days (US$37,500 in line with quarter). After the Preliminary Time period the settlement shall mechanically renew for successive quarterly sessions, each and every consisting of 3 (3) months and both celebration might terminate the settlement through offering at least thirty days prior written understand.
Arx is an arm’s-length celebration to the Corporate. Arx does no longer recently grasp any securities of VVT Med Inc.
About VVT Med Inc. (VVTM)VVT Scientific develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) answers for the remedy of vein sicknesses, beginning with varicose veins. VVT is the one FDA-cleared, standalone corporate providing NT-NT varicose vein remedy era. VVT’s FDA-cleared and CE-marked catheter-based applied sciences, ScleroSafe® and V-Block™, permit secure, office-based procedures without a anesthesia, no downtime, and minimum ache and uncomfortable side effects. Addressing the widest vary of vein diameters, VVT’s answers empower sufferers through treating each the clinical and aesthetic facets of vein illness, whilst enabling physicians to ship efficient, environment friendly, and cost-saving remedies via proprietary, simultaneous sclerosant injection and blood aspiration. The Corporate’s patented era portfolio comprises 55 patents from 14 patent households throughout 20 nations, offering large international highbrow belongings coverage via 2038. For more info, seek advice from www.vvtmed.com.
Neither the TSX Undertaking Trade nor its Legislation Products and services Supplier (as that time period is outlined within the insurance policies of the TSX Undertaking Trade) accepts accountability for the adequacy or accuracy of this unlock.
Touch InformationErez Tetro, Leader Government Officer+1 (416) 595 2991
